Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Cogent Biosciences (COGT) EBITDA Margin (2017 - 2020)

Cogent Biosciences has reported EBITDA Margin over the past 4 years, most recently at 16020.19% for Q3 2020.

  • Quarterly results put EBITDA Margin at 16020.19% for Q3 2020, down 1485127.0% from a year ago — trailing twelve months through Jun 2021 was 28707.05% (down 2861021.0% YoY), and the annual figure for FY2025 was 10745.56%, changed.
  • EBITDA Margin for Q3 2020 was 16020.19% at Cogent Biosciences, down from 1400.19% in the prior quarter.
  • Over the last five years, EBITDA Margin for COGT hit a ceiling of 15.02% in Q4 2019 and a floor of 16020.19% in Q3 2020.
  • Median EBITDA Margin over the past 4 years was 325.73% (2017), compared with a mean of 1478.0%.
  • Peak annual rise in EBITDA Margin hit 29593bps in 2020, while the deepest fall reached -1485127bps in 2020.
  • Cogent Biosciences' EBITDA Margin stood at 314.74% in 2017, then increased by 28bps to 225.86% in 2018, then skyrocketed by 107bps to 15.02% in 2019, then tumbled by -106725bps to 16020.19% in 2020.
  • The last three reported values for EBITDA Margin were 16020.19% (Q3 2020), 1400.19% (Q2 2020), and 86.67% (Q1 2020) per Business Quant data.